Abstract
Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.
| Original language | English (US) |
|---|---|
| Title of host publication | The Microbiota in Gastrointestinal Pathophysiology |
| Subtitle of host publication | Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis |
| Publisher | Elsevier |
| Pages | 135-137 |
| Number of pages | 3 |
| ISBN (Electronic) | 9780128040621 |
| ISBN (Print) | 9780128040249 |
| DOIs | |
| State | Published - Jan 1 2017 |
Keywords
- Allergy
- B632
- BB536
- BR-03
- Bifidobacterium breve strains BBG-001
- C-50 and Yakult
- CNCM I-4035
- Immunomodulation
- M-16V
- Necrotizing enterocolitis
ASJC Scopus subject areas
- Medicine(all)